<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01474187</url>
  </required_header>
  <id_info>
    <org_study_id>FDRT-003</org_study_id>
    <nct_id>NCT01474187</nct_id>
  </id_info>
  <brief_title>Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer</brief_title>
  <official_title>Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Irinotecan is one of effective drugs for colorectal cancer. In neoadjuvant chemoradiotherapy
      (CRT), Irinotecan is prescribed in a low dose of 50mg/m2/week because of toxicity. Some
      current studies showed that irinotecan's dose can be increased significantly for those
      patients with 6/6 or 6/7 genotype of UGT1A1. therefore, the investigators designed this trial
      to explore the maximal tolerable dose (MTD) of Irinotecan in combined neoadjuvant CRT.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>toxicity</measure>
    <time_frame>5 weeks</time_frame>
    <description>Grade 4 hemato-toxicity
Grade 3 nonhemato-toxicity (not include grade 3 anal verge skin toxicity)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pathological complete response (pCR)</measure>
    <time_frame>within 14days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irinotecan dose initial from 50mg/m2/week, increased by 15mg/mg/week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>initial from 50mg/m2/week and increased by 15mg/m2/week</description>
    <arm_group_label>Irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>625mg/m2,bid,d1-5,qw</description>
    <arm_group_label>Irinotecan</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>50Gy for whole pelvis</description>
    <arm_group_label>Irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with rectal adenocarcinoma

          -  Clinical staged T3/4 or any node-positive disease

          -  Age of 18-75 years

          -  Karnofsky Performance Status &gt; 80

          -  Adequate bone marrow reserve, renal and hepatic functions

          -  Without previous antitumoural chemotherapy

          -  No evidence of metastatic disease

          -  Written informed consent before randomization

          -  UGT1A1's genotype of 6/6 or 6/7

        Exclusion Criteria:

          -  Clinical staged I or IV

          -  Age of &lt;18 or &gt;75 years

          -  Karnofsky Performance Status &lt; 80

          -  Previous pelvis radiotherapy

          -  Previous antitumoural chemotherapy

          -  Clinically significant internal disease

          -  Refuse to write informed consent before randomization

          -  UGT1A1's genotype of 7/7
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ji Zhu, MD</last_name>
    <email>leo.zhu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Zhu, MD</last_name>
      <email>leo.zhu@126.com</email>
    </contact>
    <investigator>
      <last_name>Zhen Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji Zhu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2011</study_first_submitted>
  <study_first_submitted_qc>November 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2011</study_first_posted>
  <last_update_submitted>November 15, 2011</last_update_submitted>
  <last_update_submitted_qc>November 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhu Ji</investigator_full_name>
    <investigator_title>Chief of Department of Radiation Oncology, Cancer Hospital</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>rectal cancer</keyword>
  <keyword>phase I study</keyword>
  <keyword>irinotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

